

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Phospho-Stat3 (Ser727) Antibody

RRID:AB_331589

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9134, RRID:AB_331589

Antibody Information

URL: http://antibodyregistry.org/AB_331589

Proper Citation: Cell Signaling Technology Cat# 9134, RRID:AB_331589

Target Antigen: Phospho-Stat3 (Ser727)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, ChIP. Consolidation on 10/2018: AB_10078146, AB_10828368, AB_331589, AB_331590.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Stat3 (Ser727) Antibody

Description: This polyclonal targets Phospho-Stat3 (Ser727)

Target Organism: b, dg, rat, hm, hamster, h, porcine, hr, canine, m, horse, mouse, r, pg, bovine, human, mk

Antibody ID: AB_331589

Vendor: Cell Signaling Technology

Catalog Number: 9134

Record Creation Time: 20250820T004646+0000

Record Last Update: 20250820T091105+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Stat3 (Ser727) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhu YP, et al. (2025) TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice. *Acta pharmacologica Sinica*.

Bernal S, et al. (2025) Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease. *Redox biology*, 84, 103670.

Chen H, et al. (2025) DAP12 deletion reduces neuronal SLIT2 and demyelination and enhances brain resilience in female tauopathy mice. *Molecular neurodegeneration*, 20(1), 124.

Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. *Cell reports*, 44(5), 115676.

Yang L, et al. (2025) Hepatocyte metabolic adaptations during pregnancy and lactation. *Cell*.

Desmarais F, et al. (2025) A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(20), e71172.

Bancet A, et al. (2024) Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric γ pocket. *iScience*, 27(2), 108903.

Zarco N, et al. (2024) Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. *iScience*, 27(12), 111311.

Zhang K, et al. (2024) VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. *Cell reports*,

43(1), 113661.

Tang GX, et al. (2024) Mitochondrial RelA empowers mtDNA G-quadruplex formation for hypoxia adaptation in cancer cells. *Cell chemical biology*, 31(10), 1800.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8⁺ T cells. *Cell*, 187(9), 2288.

Toh SY, et al. (2024) Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to target squamous cell cancers with tyrosine kinase inhibitors. *Developmental cell*, 59(16), 2189.

Bergkamp ND, et al. (2023) A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis. *Science signaling*, 16(798), eade6737.

Meharwade T, et al. (2023) Cross-activation of FGF, NODAL, and WNT pathways constrains BMP-signaling-mediated induction of the totipotent state in mouse embryonic stem cells. *Cell reports*, 42(5), 112438.

Bohlen J, et al. (2023) Human MCTS1-dependent translation of JAK2 is essential for IFN- γ immunity to mycobacteria. *Cell*, 186(23), 5114.

Szanda G, et al. (2023) Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β -arrestin1 in complex with TC-PTP and STAT3. *iScience*, 26(7), 107207.

Yu L, et al. (2023) Large-scale production of human blastoids amenable to modeling blastocyst development and maternal-fetal cross talk. *Cell stem cell*, 30(9), 1246.

Efthymiou V, et al. (2023) Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice. *Nature communications*, 14(1), 4162.

Opazo-Ríos L, et al. (2022) Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice. *International journal of molecular sciences*, 23(7).